Nicotinamide N-methyltransferase (
NNMT) catalyzes the N-methylation of
nicotinamide using
S-adenosyl-L-methionine (SAM) as a methyl donor and, through doing so, can modulate cellular methylation potential to impact diverse epigenetic processes.
NNMT has been implicated in a range of diseases, including
cancer and metabolic disorders. Potent, selective, and cell-active inhibitors would constitute valuable probes to study the biological functions and therapeutic potential of
NNMT. We previously reported the discovery of electrophilic small molecules that inhibit
NNMT by reacting with an active-site
cysteine residue in the SAM-binding pocket. Here, we have used activity-based
protein profiling (ABPP)-guided medicinal chemistry to optimize the potency and selectivity of
NNMT inhibitors, culminating in the discovery of multiple alpha-
chloroacetamide (αCA) compounds with sub-µM IC50 values in vitro and excellent proteomic selectivity in cell lysates. However, these compounds showed much weaker inhibition of
NNMT in cells, a feature that was not shared by off-targets of the αCAs. Our results show the potential for developing potent and selective covalent inhibitors of
NNMT, but also highlight challenges that may be faced in targeting this
enzyme in cellular systems.